ArticleNature communications2019
Camouflaging bacteria by wrapping with cell membranes.
Article in Nature communications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 91 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
91 citing papers in PubMed, 238 citations in OpenAlex.
- Leveraging the bacteria for enhanced cancer immunotherapy: from a perspective of synthetic biology.Cancer biology & therapy · 2026Review
- Probiotic microcapsule polysaccharide-protein composite system: construction, mechanism and application.Archives of microbiology · 2026Review
- Bacterial engineering for cancer therapy.Nature cancer · 2026Review
- CD11b agonist GB1275 potentiates oncolytic bacterial therapy against pancreatic cancer in mouse tumor models.Nature communications · 2026Article
- Oral probiotic delivery-based therapeutic strategies for inflammatory bowel disease.Asian journal of pharmaceutical sciences · 2026Review
- From tumor targeting to tumor accessibility: surface-engineered bacteria as precision living therapeutics for translational medicine.Journal of hematology & oncology · 2026Review
- Programmable microbial therapeutics: advances in engineered bacteria for targeted in vivo delivery and precision medicine.Journal of advanced research · 2026Review
- An extrinsic enzyme-activatable fluorescent probe for high-contrast tumor imaging.Chemical science · 2026Article
- The challenges and strategies for navigatingTheranostics · 2026Review
- The renaissance ofFrontiers in immunology · 2026Review
- Advances in the engineering of living probiotics for cancer immunotherapy.Theranostics · 2026Review
- Engineering bacteria for enhanced tumor therapy: from surface modification to synthetic genetic circuits.Journal of hematology & oncology · 2025Review
- Surface modification of probiotics at single-cell resolution: Strategies, applications, and future directions in inflammatory bowel disease.Materials today. Bio · 2025Review
- Polydopamine-chitosan coated biofilm-stateMaterials today. Bio · 2025Article
- Probiotic living microneedles designed by interbacterial competition for accelerated infected wound healing.Acta pharmaceutica Sinica. B · 2025Article
- Intravenous iRGD-Guided, RBC-Membrane Camouflaged Lactococcus Lactis Remodels Cold NSCLC and Enhances PD-1 Blockade.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Progress and challenges of functionalized bacterial encapsulation: A novel biotechnology for next-generation biotherapeutics.Acta pharmaceutica Sinica. B · 2025Review
- Modulation of oral vaccine efficacy by the gut microbiota.NPJ vaccines · 2025Review
- Self-Adjusting Engineered Probiotic for Targeted Tumor Colonization and Local Therapeutics Delivery.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- A multifunctional living hydrogel for the synergistic management of infected diabetic wounds.Materials today. Bio · 2025Article
31 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacteria have been extensively utilized for bioimaging, diagnosis and therapy given their unique characteristics including genetic manipulation, rapid proliferation and disease site targeting specificity. However, clinical translation of bacteria for these applications has been largely restricted by their unavoidable side effects and low treatment efficacies. Engineered bacteria for biomedical applications ideally need to generate only a low inflammatory response, show slow elimination by macrophages, low accumulation in normal organs, and almost unchanged inherent bioactivities. Here we describe a set of stealth bacteria, cell membrane coated bacteria (CMCB), meeting these requirement. Our findings are supported by evaluation in multiple mice models and ultimately demonstrate the potential of CMCB to serve as efficient tumor imaging agents. Stealth bacteria wrapped up with cell membranes have the potential for a myriad of bacterial-mediated biomedical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.